

December 4, 2024

VIA EDGAR

United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3628

Attn: Jason Drory

Re: Marker Therapeutics, Inc. (the "Company") Registration Statement on Form S-3 File No. 333-283512

Request for Acceleration

Dear Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the "**Registrant**") respectfully requests that the Securities and Exchange Commission take appropriate action to cause the above referenced Registration Statement on Form S-3 (the "**Registration Statement**") to be declared effective at 4:00 p.m., Eastern Time, on Friday, December 6, 2024, or as soon thereafter as is practicable.

Once the Registration Statement has been declared effective, please orally confirm that event with Mark Catchur of Shumaker, Loop & Kendrick, LLP at (813) 227-2264. Thank you for your assistance in this matter.

Ver	y truly yours,
By:	/s/ Juan Vera
	Juan Vera President and Chief Executive Officer

cc: Mark A. Catchur, Shumaker, Loop & Kendrick, LLP

Marker Therapeutics, Inc. 2450 Holcombe Blvd., Suite BCM-A, MS: BCM251, Houston, TX 77021